Acid suppression and the risk of clostridium difficile infection

Journal of Pediatrics

Volumn 163, Issue 3, 2013, Pages 627-630

  Mezoff, Ethan A ^a   Cohen, Mitchell B ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

CA CDI; CDAD; CDI; Clostridium difficile infection; Clostridium difficile associated disease; Community acquired CDI; H2RA; Histamine type 2 receptor antagonist; PPI; Proton pump inhibitor

Indexed keywords

PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ACHLORHYDRIA; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; ENTERITIS; HUMAN; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH;

CA-CDI; CDAD; CDI; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE; COMMUNITY ACQUIRED CDI; H2RA; HISTAMINE TYPE 2 RECEPTOR ANTAGONIST; PPI; PROTON PUMP INHIBITOR;

ANTACIDS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; PEDIATRICS; PROTON PUMP INHIBITORS; RISK FACTORS; UNITED STATES;

EID: 84882865398     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2013.04.047     Document Type: Article

References (54)

1. C.P. Kelly, and J.T. LaMont Clostridium difficile - more difficult than ever N Engl J Med 359 2008 1932 1940
2. R.L. Jump, M.J. Pultz, and C.J. Donskey Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C difficile-associated diarrhea? Antimicrob Agents Chemother 51 2007 2883 2887
3. L. Gurian, T.T. Ward, and R.M. Katon Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection Gastroenterology 83 1982 465 469
4. A. Rao, R.L. Jump, N.J. Pultz, M.J. Pultz, and C.J. Donskey In vitro killing of nosocomial pathogens by acid and acidified nitrite Antimicrob Agents Chemother 50 2006 3901 3904
5. K.H. Wilson Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination J Clin Microbiol 18 1983 1017 1019
6. F.C. Lessa, C.V. Gould, and L.C. McDonald Current status of Clostridium difficile infection epidemiology Clin Infect Dis 55 Suppl 2 2012 S65 S70
7. J. Pepin, N. Saheb, M.A. Coulombe, M.E. Alary, M.P. Corriveau, and S. Authier Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec Clin Infect Dis 41 2005 1254 1260
8. J. Kim, S.A. Smathers, P. Prasad, K.H. Leckerman, S. Coffin, and T. Zaoutis Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006 Pediatrics 122 2008 1266 1270
9. F. Burckhardt, A. Friedrich, D. Beier, and T. Eckmanns Clostridium difficile surveillance trends, Saxony, Germany Emerging Infect Dis 14 2008 691 692
10. D. Gravel, M. Miller, A. Simor, G. Taylor, M. Gardam, and A. McGeer Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study Clin Infect Dis 48 2009 568 576
11. M.D. Zilberberg, G.S. Tillotson, and C. McDonald Clostridium difficile infections among hospitalized children, United States, 1997-2006 Emerging Infect Dis 16 2010 604 609
12. B.A. Miller, L.F. Chen, D.J. Sexton, and D.J. Anderson Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals Infect Control Hosp Epidemiol 32 2011 387 390
13. M.D. Redelings, F. Sorvillo, and L. Mascola Increase in Clostridium difficile-related mortality rates, United States, 1999-2004 Emerging infectious diseases 13 2007 1417 1419
14. R. Ricciardi, D.A. Rothenberger, R.D. Madoff, and N.N. Baxter Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States Arch Surg 142 2007 624 631 discussion 31
15. C.A. Muto, M. Pokrywka, K. Shutt, A.B. Mendelsohn, K. Nouri, and K. Posey A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use Infect Control Hosp Epidemiol 26 2005 273 280
16. P.K. Kutty, C.W. Woods, A.C. Sena, S.R. Benoit, S. Naggie, and J. Frederick Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina USA. Emerg Infect Dis 16 2010 197 204
17. S. Khanna, D.S. Pardi, S.L. Aronson, P.P. Kammer, R. Orenstein, and J.L. St Sauver The epidemiology of community-acquired Clostridium difficile infection: a population-based study Am J Gastroenterol 107 2012 89 95
18. C.M. Nylund, A. Goudie, J.M. Garza, G. Fairbrother, and M.B. Cohen Clostridium difficile infection in hospitalized children in the United States Arch Pediatr Adolesc Med 165 2011 451 457
19. S. Khanna, L.M. Baddour, W.C. Huskins, P.P. Kammer, W.A. Faubion, and A.R. Zinsmeister The epidemiology of Clostridium difficile infection in children: a population-based study Clin Infect Dis 107 2013 89 95
20. J.R. O'Connor, S. Johnson, and D.N. Gerding Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain Gastroenterology 136 2009 1913 1924
21. L.C. McDonald, G.E. Killgore, A. Thompson, R.C. Owens Jr., S.V. Kazakova, and S.P. Sambol An epidemic, toxin gene-variant strain of Clostridium difficile N Engl J Med 353 2005 2433 2441
22. S. Naggie, B.A. Miller, K.B. Zuzak, B.W. Pence, A.J. Mayo, and B.P. Nicholson A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors Am J Med 124 2011 276.e1 276.e7
23. M.P. Hensgens, A. Goorhuis, D.W. Notermans, B.H. van Benthem, and E.J. Kuijper Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in The Netherlands Euro surveillance Eur Commun Dis Bull 14 2009 45
24. M.P. Bauer, D.W. Notermans, B.H. van Benthem, J.S. Brazier, M.H. Wilcox, and M. Rupnik Clostridium difficile infection in Europe: a hospital-based survey Lancet 377 2011 63 73
25. J. Leonard, J.K. Marshall, and P. Moayyedi Systematic review of the risk of enteric infection in patients taking acid suppression Am J Gastroenterol 102 2007 2047 2056 quiz 57
26. Y. Lu, E. Sverden, R. Ljung, C. Soderlund, and J. Lagergren Use of non-steroidal anti-inflammatory drugs and proton pump inhibitors in correlation with incidence, recurrence and death of peptic ulcer bleeding: an ecological study BMJ 3 2013 1
27. M.L. Schubert Gastric secretion Curr Opin Gastroenterol 24 2008 659 664
28. R.H. Hunt, C. Cederberg, J. Dent, F. Halter, C. Howden, and I.N. Marks Optimizing acid suppression for treatment of acid-related diseases Dig Dis Sci 40 2 Suppl 1995 24S 49S
29. P. Miner Jr., P.O. Katz, Y. Chen, and M. Sostek Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2003 2616 2620
30. J. Kirchheiner, S. Glatt, U. Fuhr, U. Klotz, I. Meineke, and T. Seufferlein Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH Eur J Clin Pharmacol 65 2009 19 31
31. S.M. Tennant, E.L. Hartland, T. Phumoonna, D. Lyras, J.I. Rood, and R.M. Robins-Browne Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens Infect Immunity 76 2008 639 645
32. K. Zedtwitz-Liebenstein, C. Wenisch, S. Patruta, B. Parschalk, F. Daxbock, and W. Graninger Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity Crit Care Med 30 2002 1118 1122
33. J.H. Wandall Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245 Gut 33 1992 617 621
34. G. Agastya, B.C. West, and J.M. Callahan Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro Immunopharmacol Immunotoxicol 22 2000 357 372
35. C. Bavishi, and H.L. Dupont Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection Alimentary Pharmacol Therapeut 34 2011 1269 1281
36. E. Brown, G.H. Talbot, P. Axelrod, M. Provencher, and C. Hoegg Risk factors for Clostridium difficile toxin-associated diarrhea Infect Control Hosp Epidemiol 11 1990 283 290
37. S. Janarthanan, I. Ditah, D.G. Adler, and M.N. Ehrinpreis Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis Am J Gastroenterol 107 2012 1001 1010
38. A. Deshpande, C. Pant, V. Pasupuleti, D.D. Rolston, A. Jain, and N. Deshpande Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Clin Gastroenterol Hepatol 10 2012 225 233
39. C.S. Kwok, A.K. Arthur, C.I. Anibueze, S. Singh, R. Cavallazzi, and Y.K. Loke Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis Am J Gastroenterol 107 2012 1011 1019
40. J.L. Kuntz, E.A. Chrischilles, J.F. Pendergast, L.A. Herwaldt, and P.M. Polgreen Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study BMC Infect Dis 11 2011 194
41. M.D. Howell, V. Novack, P. Grgurich, D. Soulliard, L. Novack, and M. Pencina Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection Arch Int Med 170 2010 784 790
42. R. Turco, M. Martinelli, E. Miele, E. Roscetto, M. Del Pezzo, and L. Greco Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection Alimentary Pharmacol Therapeut 31 2010 754 759
43. S.R. Schwartz, S.M. Cohen, S.H. Dailey, R.M. Rosenfeld, E.S. Deutsch, and M.B. Gillespie Clinical practice guideline: hoarseness (dysphonia) Otolaryngology Head Neck Surgery 141 3 Suppl 2 2009 S1 S31
44. G.T. Furuta, C.A. Liacouras, M.H. Collins, S.K. Gupta, C. Justinich, and P.E. Putnam Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment Gastroenterology 133 2007 1342 1363
45. S. Koletzko, N.L. Jones, K.J. Goodman, B. Gold, M. Rowland, and S. Cadranel Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children J Pediatr Gastroenterol Nutr 53 2011 230 243
46. Y. Vandenplas, C.D. Rudolph, C. Di Lorenzo, E. Hassall, G. Liptak, and L. Mazur Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) J Pediatr Gastroenterol Nutr 49 2009 498 547
47. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998 AJHP 56 1999 347 379
48. B.C. Jacobson, T.G. Ferris, T.L. Shea, E.M. Mahlis, T.H. Lee, and T.C. Wang Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98 2003 51 58
49. J.J. Heidelbaugh, K.L. Goldberg, and J.M. Inadomi Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting Am J Manage Care 16 2010 e228 e234
50. J.M. Inadomi, L. McIntyre, L. Bernard, and A.M. Fendrick Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs Am J Gastroenterol 98 2003 1940 1944
51. J.M. Inadomi, R. Jamal, G.H. Murata, R.M. Hoffman, L.A. Lavezo, and J.M. Vigil Step-down management of gastroesophageal reflux disease Gastroenterology 121 2001 1095 1100
52. J.J. Heidelbaugh, A.H. Kim, R. Chang, and P.C. Walker Overutilization of proton-pump inhibitors: what the clinician needs to know Therapeut Adv Gastroenterol 5 2012 219 232
53. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs): U.S. Food and Drug Administration; 2012 [updated 02/15/1302/27/13]. Available at: http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed February, 17, 2013.
54. E. Mezoff, E.A. Mann, K.W. Hart, C.J. Lindsell, and M.B. Cohen Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population J Pediatr Gastroenterol Nutr 52 2011 437 441